Quince Therapeutics (QNCX) Treasury Shares (2018 - 2026)

Quince Therapeutics (QNCX) posted Treasury Shares of $211301.9 for Q2 2026, down 97.69% on a QoQ basis from $9.2 million in Q1 2019.

Analysis

Quince Therapeutics (QNCX) Treasury Shares (2018 - 2026) Analysis & Trends

Quince Therapeutics has reported Treasury Shares for 3 years, with the latest figure at $211301.9 in Q2 2026.

On a quarterly basis, Treasury Shares changed N/A year-over-year to $211301.9 in Q2 2026; TTM through Jun 2026 was $211301.9, a N/A change from a year earlier, with the FY2018 full-year figure at $9.2 million, changed N/A from the prior year.
Treasury Shares was $211301.9 for Q2 2026 at Quince Therapeutics, down from $9.2 million in the prior quarter.
The five-year high for Treasury Shares was $211301.9 in Q2 2026, with the low at $211301.9 in Q2 2026.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Treasury Shares (Qtr)
1	Amgen	206.44 Bn	192.45 Bn	7.24 Bn	-
2	Gilead Sciences	179.97 Bn	176.79 Bn	6.22 Bn	-
3	Vertex Pharmaceuticals	130.57 Bn	122.72 Bn	2.84 Bn	-
4	Regeneron Pharmaceuticals	81.63 Bn	73.63 Bn	3.93 Bn	36.40 Mn
5	Argenx Se	60.34 Bn	55.16 Bn	1.37 Bn	-
6	Moderna	54.37 Bn	49.23 Bn	52.00 Mn	-
7	Alnylam Pharmaceuticals	33.07 Bn	29.76 Bn	992.69 Mn	-
8	Biogen	31.84 Bn	30.55 Bn	1.96 Bn	-23.80 Mn
9	Roivant Sciences	29.49 Bn	29.49 Bn	1.16 Mn	-
10	Quince Therapeutics	175.52 Mn	175.52 Mn	-	211,301.87

Historic Data

Download Data